Anti-A4/ APP/ AAA monoclonal antibody

Anti-A4/ APP/ AAA antibody for FACS & in-vivo assay

Target products collectionGo to APP/APP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T87024-Ab-1/ GM-Tg-hg-T87024-Ab-2Anti-Human APP monoclonal antibodyHuman
GM-Tg-rg-T87024-Ab-1/ GM-Tg-rg-T87024-Ab-2Anti-Rat APP monoclonal antibodyRat
GM-Tg-mg-T87024-Ab-1/ GM-Tg-mg-T87024-Ab-2Anti-Mouse APP monoclonal antibodyMouse
GM-Tg-cynog-T87024-Ab-1/ GM-Tg-cynog-T87024-Ab-2Anti-Cynomolgus/ Rhesus macaque APP monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T87024-Ab-1/ GM-Tg-felg-T87024-Ab-2Anti-Feline APP monoclonal antibodyFeline
GM-Tg-cang-T87024-Ab-1/ GM-Tg-cang-T87024-Ab-2Anti-Canine APP monoclonal antibodyCanine
GM-Tg-bovg-T87024-Ab-1/ GM-Tg-bovg-T87024-Ab-2Anti-Bovine APP monoclonal antibodyBovine
GM-Tg-equg-T87024-Ab-1/ GM-Tg-equg-T87024-Ab-2Anti-Equine APP monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T87024-Ab-1/ GM-Tg-hg-T87024-Ab-2; GM-Tg-rg-T87024-Ab-1/ GM-Tg-rg-T87024-Ab-2;
GM-Tg-mg-T87024-Ab-1/ GM-Tg-mg-T87024-Ab-2; GM-Tg-cynog-T87024-Ab-1/ GM-Tg-cynog-T87024-Ab-2;
GM-Tg-felg-T87024-Ab-1/ GM-Tg-felg-T87024-Ab-2; GM-Tg-cang-T87024-Ab-1/ GM-Tg-cang-T87024-Ab-2;
GM-Tg-bovg-T87024-Ab-1/ GM-Tg-bovg-T87024-Ab-2; GM-Tg-equg-T87024-Ab-1/ GM-Tg-equg-T87024-Ab-2
Products NameAnti-APP monoclonal antibody
Formatmab
Target NameAPP
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-APP benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-011Pre-Made Aducanumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-527Pre-Made Solanezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-232Pre-Made Gantenerumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-046Pre-Made Bapineuzumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-450Pre-Made Ponezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-153Pre-Made Donanemab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-300Pre-Made Lecanemab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    BiosimilarGMP-Bios-ab-122Pre-Made Crenezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
    Target AntigenProducts DevelopingMulti-species A4/ APP/ AAA VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMAD000406human APP Adenovirus plasmid
    ORF Viral VectorvGMAD000012human APP Adenovirus particle
    ORF Viral VectorvGMLV000767human APP Lentivirus particle
    ORF Viral VectorvGMAD000406human APP Adenovirus particle
    ORF Viral VectorvGMLV000448human APP Lentivirus particle
    ORF Viral VectorpGMLV000448human APP Lentivirus plasmid
    ORF Viral VectorvGMLV000006human APP Lentivirus particle
    ORF Viral VectorpGMAD000012human APP Adenovirus plasmid
    ORF Viral VectorvGMAP000180Human APP Adenovirus particle
    ORF Viral VectorpGMLV000006human APP Lentivirus plasmid
    ORF Viral VectorpGMAP000180Human APP Adenovirus plasmid
    ORF Viral VectorpGMLV000767human APP Lentivirus plasmid


    Target information

    Target IDGM-T87024
    Target NameAPP
    Gene ID351,11820,54226,100427716,403407,101085564,280722,100066294
    Gene Symbol and SynonymsAAA,ABETA,ABPP,AD1,Adap,Ag,alpha-sAPP,APP,APPI,betaApp,CTFgamma,CVAP,E030013M08Rik,PN-II,PN2,preA4
    Uniprot AccessionP05067,P08592,P29216,Q28280,P86906,Q28053
    Uniprot Entry NameA4_HUMAN,A4_MACMU,A4_RAT,A4_FELCA,A4_CANLF,A4_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000142192
    Target ClassificationN/A

    The target: APP, gene name: APP, also named as AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, preA4, APP. This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.